Want to see DNA full AI Analyst Report?
Operating Income by Segment
Reveals profitability across different business units, highlighting which segments drive earnings and where there may be challenges or opportunities for growth.Cell Engineering’s outsized operating losses from 2022–early 2023 have narrowed materially since late 2024, suggesting meaningful cost discipline, project rationalization, or early revenue realization that materially cuts cash burn. Biosecurity, which delivered strong, lumpy profits in 2021–2022, has normalized into modest, steady losses—consistent with waning one‑off contract tailwinds. Together these moves point to a shift from heavy scale‑up spending toward operational consolidation, but persistent quarter‑to‑quarter volatility means profitability still hinges on sustained commercial wins or new large contracts.
Date | Cell Engineering | Biosecurity |
|---|---|---|
Jun 30, 2026 | -$57.19M | $0.00 |
Mar 31, 2026 | -$71.37M | $0.00 |
Dec 31, 2025 | -$17.27M | -$4.05M |
Sep 30, 2025 | -$36.74M | -$4.88M |
Jun 30, 2025 | -$9.94M | -$4.82M |
Mar 31, 2025 | -$31.59M | -$5.18M |
Dec 31, 2024 | -$38.14M | -$9.75M |
Sep 30, 2024 | -$13.45M | -$6.21M |
Jun 30, 2024 | -$95.81M | -$3.44M |
Mar 31, 2024 | -$92.25M | -$11.22M |